Free Trial

Mural Oncology (MURA) Competitors

Mural Oncology logo
$2.46 -0.02 (-0.81%)
Closing price 04:00 PM Eastern
Extended Trading
$2.46 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MURA vs. CYBN, RAPT, TLSA, ACOG, BDTX, DERM, KYTX, ACRS, BIOA, and IPHA

Should you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Cybin (CYBN), Rapt Therapeutics (RAPT), Tiziana Life Sciences (TLSA), Alpha Cognition (ACOG), Black Diamond Therapeutics (BDTX), Journey Medical (DERM), Kyverna Therapeutics (KYTX), Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.

Mural Oncology vs. Its Competitors

Cybin (NYSE:CYBN) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Cybin currently has a consensus price target of $85.00, indicating a potential upside of 957.21%. Mural Oncology has a consensus price target of $12.00, indicating a potential upside of 387.80%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Mural Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Mural Oncology
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Cybin's return on equity of -37.58% beat Mural Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -37.58% -36.59%
Mural Oncology N/A -83.39%-70.70%

Cybin is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$57.88M-$3.88-2.07
Mural OncologyN/AN/A-$128.51M-$7.67-0.32

17.9% of Cybin shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 2.2% of Mural Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Mural Oncology had 5 more articles in the media than Cybin. MarketBeat recorded 5 mentions for Mural Oncology and 0 mentions for Cybin. Cybin's average media sentiment score of 0.50 beat Mural Oncology's score of -0.24 indicating that Cybin is being referred to more favorably in the media.

Company Overall Sentiment
Cybin Positive
Mural Oncology Neutral

Cybin has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500.

Summary

Cybin beats Mural Oncology on 10 of the 14 factors compared between the two stocks.

Get Mural Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MURA vs. The Competition

MetricMural OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$42.83M$2.52B$5.70B$9.48B
Dividend YieldN/A1.76%4.59%3.99%
P/E Ratio-0.329.1227.9019.95
Price / SalesN/A746.51442.19102.72
Price / CashN/A166.2336.5558.97
Price / Book0.305.228.635.90
Net Income-$128.51M$30.99M$3.24B$258.42M
7 Day Performance-1.20%4.29%3.22%1.94%
1 Month Performance0.82%13.40%10.72%12.02%
1 Year Performance-28.28%0.59%34.94%20.81%

Mural Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MURA
Mural Oncology
3.2609 of 5 stars
$2.46
-0.8%
$12.00
+387.8%
-28.1%$42.83MN/A-0.32119News Coverage
CYBN
Cybin
2.7446 of 5 stars
$7.38
-1.3%
$85.00
+1,052.5%
N/A$171.53MN/A-1.7050
RAPT
Rapt Therapeutics
4.3256 of 5 stars
$10.30
+18.1%
$19.80
+92.3%
-42.9%$171.27M$1.53M-0.5480News Coverage
Analyst Upgrade
High Trading Volume
TLSA
Tiziana Life Sciences
1.2141 of 5 stars
$1.45
-2.4%
N/A+97.8%$168.85MN/A0.008
ACOG
Alpha Cognition
1.1348 of 5 stars
$10.47
-0.6%
$20.00
+91.0%
N/A$167.73M$2.93M-8.72N/APositive News
BDTX
Black Diamond Therapeutics
2.2165 of 5 stars
$2.93
-0.5%
$12.80
+337.6%
-48.6%$166.88MN/A48.9290
DERM
Journey Medical
1.0447 of 5 stars
$7.13
-3.8%
$9.50
+33.2%
+36.6%$166.71M$56.13M-18.3590Positive News
KYTX
Kyverna Therapeutics
1.9695 of 5 stars
$3.83
-13.0%
$18.50
+383.0%
-54.0%$165.75M$7.03M-1.1396Positive News
ACRS
Aclaris Therapeutics
1.7182 of 5 stars
$1.53
-3.5%
$8.71
+471.4%
+20.0%$165.13M$18.72M-1.10100
BIOA
BioAge Labs
N/A$4.49
-3.0%
N/AN/A$160.97MN/A0.00N/A
IPHA
Innate Pharma
1.9102 of 5 stars
$1.76
+3.2%
$11.00
+526.8%
-10.9%$160.39M$21.77M0.00220Positive News

Related Companies and Tools


This page (NASDAQ:MURA) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners